TABLE 2.
Relationships between expression of CD271 and clinicopathological factors
| Factor | Patients | CD271 (invasive/central/whole) | P value (invasive/central/whole) | |||
|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | |||
| Age (y) | ||||||
| <50 | 32 | 7/12/6 | 11/15/19 | 9/3/5 | 5/2/2 | .943/.408/.400 |
| ≧50 | 88 | 23/48/21 | 26/14/37 | 24/17/21 | 15/9/9 | |
| Gender | ||||||
| Male | 88 | 23/43/21 | 24/19/36 | 24/16/21 | 17/10/10 | .387/.311/.143 |
| Female | 32 | 7/17/6 | 13/10/20 | 9/4/5 | 3/1/1 | |
| T classification | ||||||
| T1 | 28 | 8/13/6 | 11/7/14 | 5/5/5 | 4/3/3 | .075/.364/.140 |
| T2 | 37 | 13/24/13 | 13/8/17 | 6/3/5 | 5/2/2 | |
| T3 | 51 | 7/21/6 | 12/12/23 | 21/12/16 | 11/6/6 | |
| T4 | 4 | 2/2/2 | 1/2/2 | 1/0/0 | 0/0/0 | |
| N classification | ||||||
| N0 | 56 | 13/29/12 | 20/13/28 | 16/11/13 | 7/3/3 | .09/.331/.276 |
| N1 | 30 | 9/18/9 | 11/8/15 | 8/3/5 | 2/1/1 | |
| N2 | 29 | 8/12/6 | 4/6/10 | 7/5/7 | 10/6/6 | |
| N3 | 5 | 0/1/0 | 2/2/3 | 2/1/1 | 1/1/1 | |
| ly classification | ||||||
| ly0 | 12 | 4/7/4 | 3/1/4 | 3/3/3 | 2/1/1 | .250/.250/.418 |
| ly1 | 29 | 9/17/8 | 11/7/4 | 4/3/5 | 5/2/2 | |
| ly2 | 50 | 12/22/10 | 13/15/24 | 20/11/14 | 5/2/2 | |
| ly3 | 29 | 5/14/5 | 10/6/14 | 6/3/4 | 8/6/6 | |
| V classification | ||||||
| V0 | 39 | 14/23/12 | 14/9/18 | 8/6/8 | 3/1/1 | .050/.021/.035 |
| V1 | 65 | 12/28/11 | 19/19/32 | 23/13/17 | 11/5/5 | |
| V2 | 16 | 4/9/4 | 4/1/6 | 2/1/1 | 6/5/5 | |
| V3 | 0 | 0/0/0 | 0/0/0 | 0/0/0 | 0/0/0 | |
| Tissue type | ||||||
| tub | 43 | 9/18/7 | 12/12/19 | 14/11/15 | 8/2/2 | .463/.045/.115 |
| pap | 20 | 8/16/7 | 7/2/11 | 4/1/1 | 1/1/1 | |
| por | 28 | 6/15/6 | 9/4/13 | 8/4/4 | 5/5/5 | |
| muc | 5 | 3/3/3 | 0/2/1 | 1/0/1 | 1/0/0 | |
| sig | 24 | 4/8/4 | 9/9/12 | 6/4/5 | 5/3/3 | |
| Stage | ||||||
| I | 45 | 12/24/11 | 19/11/23 | 7/6/7 | 7/4/4 | .042/.102/.142 |
| II | 29 | 10/19/9 | 7/5/13 | 11/5/7 | 1/0/0 | |
| III | 26 | 5/10/4 | 7/9/13 | 9/5/7 | 5/2/2 | |
| IV | 20 | 3/7/3 | 4/4/7 | 6/4/5 | 7/5/5 | |
| Stromal volume | ||||||
| med | 55 | 16/36/15 | 23/10/30 | 10/5/6 | 6/4/4 | .024/.085/.071 |
| int | 29 | 7/10/5 | 3/8/9 | 11/8/12 | 8/3/3 | |
| sci | 36 | 7/14/7 | 11/11/17 | 12/7/8 | 6/4/4 | |
| INF | ||||||
| a | 47 | 15/32/14 | 16/5/22 | 10/5/6 | 6/5/5 | .396/.015/.280 |
| b | 44 | 9/17/7 | 15/16/22 | 11/9/13 | 9/2/2 | |
| c | 29 | 6/11/6 | 6/8/12 | 12/6/7 | 5/4/4 | |
T1 tumor confined to the submucosa, T2 tumor invades the muscularis propria, T3 tumor invades the subserosa, T4 tumor invasion is contiguous to or exposed beyond the serosa or tumor invades adjacent structures, N0 no regional lymph node metastasis, N1 metastasis in one to two regional lymph nodes, N2 metastasis in three to six regional lymph nodes, N3 metastasis in seven or more regional lymph nodes, ly0 no lymphatic invasion, ly1 minimal lymphatic invasion, ly2 moderate lymphatic invasion, ly3 marked lymphatic invasion, v0 no venous invasion, v1 minimal venous invasion, v2 moderate venous invasion, v3 marked venous invasion, tub tubular adenocarcinoma, pap papillary adenocarcinoma, por poorly differentiated adenocarcinoma, muc mucinous adenocarcinoma, sig signet‐ring cell carcinoma, med sparse stroma, sci abundant stroma, int the quality of stroma is intermediate between med and sci, INFa tumor displays expanding growth with a distinct border from the surrounding tissue, INFb tumor shows an intermediate pattern between INFa and INFc, INFc tumor displays infiltrative growth with no distinct border with the surrounding tissue.